An interventional study of Intalight Dream OCT and Heidelberg Spectralis OCT in Ocular Tumor, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Eye Neoplasms with a site in United States — 4 open to participants now, 8 under way, 1 of them phase 3. Eye Neoplasms · United States.
Among the 22 studies in Eye Neoplasms with a site in United States, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 2 with no phase, and was the 22nd registered.
32 studies on the registry are indexed under Eye Neoplasms; 4 are open to participants now.
Browse Eye Neoplasms studies →4 of the 22 studies in Eye Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Novelwise Pharmaceutical Corporation · Sites in United States
Ages 18+
Aura Biosciences · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 4 wk+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Eye Neoplasms studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 2
First in 2000; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 36 across 19 interventional studies indexed under Eye Neoplasms.
Median enrollment 40 across the 15 interventional studies, 33 across the 5 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 22 have an industry lead sponsor. The 10 most frequent:
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
Memorial Sloan Kettering Cancer Center has 2 studies filed under Eye Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Eye Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06007690Phase 3Aura BiosciencesA Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | 2027-11-15 |
| NCT06643884Aura BiosciencesSuprachoroidal Administration in Subjects With Metastases to the Choroid | 2026-11-30 |
| NCT01653080University of CincinnatiMRI in Diagnosing Solid Tumors of the Eye and Orbit | 2026-12-31 |
| NCT03713268Duke UniversityIntraoperative OCT Guidance of Intraocular Surgery II | 2026-12-31 |
| NCT05415072Novartis PharmaceuticalsA Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies in Eye Neoplasms with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare two devices used for optical coherence tomography (OCT). OCT is a noninvasive imaging (scanning) method that uses reflected light to create pictures of the back of the eye, and doctors can use OCT to detect and monitor different types of cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will have at least 1 eye that has an intraocular or ocular surface tumor.
Diagnostic Test: Intalight Dream OCT · Diagnostic Test: Heidelberg Spectralis OCT
This is a next-generation swept-source device that has a faster imaging speed and higher sensitivity than the previous generation of frequency-domain OCT devices, which serve as the current standard of care devices.
This is the standard of care for optical imaging.
Image quality for participants
Evaluated by next-generation swept-source OCT versus standard OCT for imaging of the eye and any relevant ocular tumors.
Time frame: Up to 1 year
Field of view for participants
Evaluated by next-generation swept-source OCT versus standard OCT for imaging of the eye and any relevant ocular tumors.
Time frame: Up to 1 year
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →